Mologen reported earnings results for the year 2014. For the period, the company reported net loss for the year of EUR 17.1 million was essentially attributable to the increase in expenses for research and development as a result of these studies. R&D expenditure amounted to EUR 13.3 million against EUR 7.9 million due to the start of the IMPALA and IMPULSE studies.